BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/22/2014 5:28:00 PM | Browse: 1283 | Download: 1427
 |
Received |
|
2013-12-19 11:40 |
|
Peer-Review Started |
|
2013-12-19 15:44 |
 |
First Decision by Editorial Office Director |
|
|
|
Return for Revision |
|
2014-03-22 16:40 |
|
Revised |
|
2014-04-08 21:14 |
|
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2014-05-29 08:46 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2014-05-29 09:32 |
|
Articles in Press |
|
2014-05-29 10:45 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2014-07-21 16:17 |
|
Publish the Manuscript Online |
|
2014-08-01 15:17 |
| Category |
Oncology |
| Manuscript Type |
Topic Highlights |
| Article Title |
Toremifene in the treatment of breast cancer
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Mika VJ Mustonen, Seppo Pyrhönen and Pirkko-Liisa Kellokumpu-Lehtinen |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Mika VJ Mustonen, PhD, Orion Corporation, Orion Pharma, Orionintie 1, FIN-02101, Espoo, Finland. mika.mustonen@orionpharma.com |
| Key Words |
Breast cancer; Toremifene; tamoxifen; Adjuvant treatment; Advanced breast cancer |
| Core Tip |
Toremifene is safe and effective in the treatment of breast cancer. Toremifene and tamoxifen are equivalently effective in the treatment of breast cancer, although some studies show an advantage for toremifene. Safety and tolerability is also broadly equivalent, although toremifene may cause fewer uterine neoplasms, serious vascular adverse events and has a more beneficial effect on plasma lipids than does tamoxifen. |
| Publish Date |
2014-08-01 15:17 |
| Citation |
Mustonen MVJ, Pyrhönen S, Kellokumpu-Lehtinen PL. Toremifene in the treatment of breast cancer. World J Clin Oncol 2014; 5(3): 393-405 |
| URL |
http://www.wjgnet.com/2218-4333/full/v5/i3/393.htm |
| DOI |
http://dx.doi.org/10.5306/wjco.v5.i3.393 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
